Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-beta1b for multiple sclerosis.

Jack Burks1

  • 1University of Nevada, School of Medicine, Reno, NV, USA. jack@jackburks.com

Expert Review of Neurotherapeutics
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.

ClinicoEconomics and outcomes research : CEOR·2017
Same author

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis.

International journal of MS care·2015
Same author

The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis.

Neurourology and urodynamics·2014
Same author

Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients.

International journal of MS care·2014
Same author

Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.

BMC neurology·2013
Same journal

Innovation is not enough: lessons from lasmiditan for real-world effectiveness in acute migraine therapy.

Expert review of neurotherapeutics·2026
Same journal

Can the integration of blood-based biomarkers into Alzheimer's disease diagnosis revolutionize the field?

Expert review of neurotherapeutics·2026
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
See all related articles

Interferon-beta1b is a proven first-line therapy for relapsing multiple sclerosis, demonstrating long-term efficacy and improved tolerability. Patient adherence is enhanced through autoinjectors and supportive care strategies.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Interferon-beta1b was the first approved therapy for relapsing-remitting multiple sclerosis (RRMS).
  • The FDA expanded its indication to include relapsing forms of multiple sclerosis, including secondary-progressive multiple sclerosis (SPMS) with active relapses.

Observation:

  • Head-to-head trials show interferon-beta1b is clinically superior to low-dose interferon-beta1a.
  • Ongoing studies compare interferon-beta1b with higher doses and glatiramer acetate.
  • Neutralizing antibody occurrence is higher with interferon-beta1b, but clinical significance remains uncertain.

Findings:

  • Long-term (up to 12 years) data indicate sustained effectiveness on MRI T2 lesion burden in patients continuing therapy.
  • Initial tolerability issues (skin reactions, flu-like symptoms) have been mitigated by improved administration protocols and patient support.

Related Experiment Videos

Implications:

  • Interferon-beta1b remains a valuable first-line treatment for specific MS types due to robust efficacy and established safety.
  • Enhanced patient adherence strategies contribute to sustained therapeutic benefits in multiple sclerosis management.